Health Trials

Prurigo Nodularis (PN)

3

Review clinical trials related to Prurigo Nodularis (PN). Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

Efficacy and Speed of Response of Lebrikizumab in High-Burden Prurigo Nodularis Patients

The purpose of this study is to evaluate the effectiveness of lebrikizumab in treating adults with moderate-to-severe Prurigo Nodularis (PN).

Participants needed: 15
Trial details
Phase: Phase 2Age: 18-80Biological sex: AllType: InterventionalSponsor: University of Maryland, BaltimoreUpdated: Jun 2, 2026Locations: 1
Eligibility criteria

Age 18-80 [+4]

Prior participation in a lebrikizumab study [+15]

Read more
Status: Recruiting

Study of the Efficacy and Safety of ICP-332 in Participants With Prurigo Nodularis

Evaluate the efficacy and safety of ICP-332 in participants with Prurigo Nodularis (PN)

Participants needed: 135
Trial details
Phase: Phase 2Age: 18-75Biological sex: AllType: InterventionalSponsor: Beijing InnoCare Pharma Tech Co., Ltd.Updated: Apr 9, 2026Locations: 16
Eligibility criteria

Voluntarily sign informed consent forms before any investigational procedure(s)... [+6]

Patients with a documented AD severity moderate to severe presence of skin morbi... [+1]

Read more
Status: Recruiting

Early and Long-Term Efficacy and Immune Changes With Dupilumab in Prurigo Nodularis

With the arrival of dupilumab as the first available targeted therapy for PN, there is an unmet need for real-world data and translational research on the working mechanism of dupilumab on PN, to optimize individualized targeted treatment.

Participants needed: 40
Trial details
Age: 18+Biological sex: AllType: ObservationalSponsor: UMC UtrechtUpdated: Dec 18, 2025Locations: 1Duration: 52 Weeks
Eligibility criteria

Adult patients with moderate-to-severe prurigo nodularis starting dupilumab trea...

Unwilling to participate in the BioDay registry [+1]

Read more